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Purpose/Objective: The aim of this study is to validate a 
frameless approach for the integration of two-dimensional 
(2D) digital subtracted angiography (DSA) images with three-
dimensional (3D) computed tomography angiography (CTA) 
and magnetic resonance angiography (MRA) datasets using 
vessel tree segmentation for image registration for 
arteriovenous malformation (AVM) radiosurgery. 
Materials and Methods: A retrospective analysis of 28 AVM 
patients with DSA, CTA and MRA imaging was performed. 
Vessel tree segmentation of CTA/MRA was used to register 
these 3D-image sets with 2D DSA. AVM contouring on DSA is 
projected on the CTA/MRA and used as a guide to segment 
and delineate the lesion on CTA and MRA. Based on these 
contours, the localization accuracy was evaluated comparing 
the new vessel tree-based image registration (frameless 
approach) with external coordinates localization (frame-
based approach).  
Results: In all 28 cases, a vessel tree could be mapped out of 
CTA and MRA datasets and used to register with DSA. DSA 
contouring resulting in a 3D AVM contour on CTA showed a 
mean volume of 1.60 cc for both approaches. The targeting 
accuracy of the new application with vessel tree 
segmentation was found 0.4 ± 0.3 mm, 0.5 ± 0.3 mm and 0.3 
± 0.3 mm for the CC, LAT and AP direction, respectively, 
resulting in an overall 3D vector of 0.8 ± 0.4 mm. The 
agreement ratio, which reflects the similarity between the 
two approaches, was 0.75 ± 0.12. 
Conclusions: Registration of 2D DSA images with 3D CTA/MRA 
based on vessel tree segmentation is a feasible option for 
frameless AVM targeting and showed submillimetric targeting 
accuracy.  
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Purpose/Objective: MLC tracking is a promising method for 
intrafraction tumor motion management by real-time 
adaption of the MLC aperture to the moving target. However, 
limitations in MLC adaptation leads to residual dosimetric 
errors. Here, we present an MLC tracking simulator and 
demonstrate its use for large-scale simulations to quantify 
the dosimetric benefit of potential tracking system design 
improvements 
Materials and Methods: A Varian TrueBeam accelerator with 
MLC tracking guided by the Calypso electromagnetic 
transponder system was used as reference for the simulator. 
The Calypso system delivers a 3D position of the target every 
40ms to the tracking system. Similar to the accelerator, the 
tracking simulator performs three steps every 10ms. 1) 
Estimate the target position, 2) fit the MLC shape to the 
estimated target position, and 3) adjust the MLC leaves to 
the fitted MLC shape. For each of these three steps, the 
residual adaptation error was quantified by the under-
exposed area Au (MLC shielded area that should ideally be 
exposed) and the over-exposed area Ao (MLC exposed area 
that should ideally be shielded). It has previously been shown 
that Au+Ao is a good surrogate for the dosimetric error. 
Tracking log files from the accelerator were analyzed and 
used to build the MLC dynamics into the simulator. 
The MLC tracking simulator was used to test the following 
potential improvements of the tracking system: A) Halving 
the latency (improves target localization), B) Halving the MLC 
leaf width from 5 mm to 2.5 mm (improves MLC fitting), C) 
Dynamic alignment of the collimator during arc treatments 
such that the leaves move along a preferred target motion 
direction (improves MLC fitting). For all potential 
improvements, the reduction in Au+Ao was calculated and 
used to test whether the improvement was statistically 
significant. The base system and each simulated improved 
system were tested with two high-modulated VMAT plans 
(lung and prostate) for 100 patient-measured tumor traces 
from motion databases (50 lung and 50 prostate). Only traces 
with motion larger than 5 mm were chosen for the 
simulations. 
Results: For lung, the mean Au+Ao was on average reduced 
by 5.4 % (Half latency, p= 0.00), 23.5 % (Half leaf width, p= 
0.00) and 10.8 % (Dynamic collimator rotation, p= 0.04) by 
the tested tracking system improvements. For prostate, 
Au+Ao was reduced by 6.36 % (Half latency, p= 0.00), 21.1% 
(Half leaf with, p= 0.00) and 8 % (Dynamic collimator 
rotation, p= 0.10). The figure illustrates that for both tumor 
sites, the primary source of residual errors is leaf fitting, 
followed by leaf adjustment errors for lung tumor motion and 
by errors caused by the latency for prostate motion. 
 
Conclusions: A framework for MLC tracking simulations was 
built. All system modification simulated gave a reduction of 
the residual error, however it was not statistical significant 
for prostate and collimator rotation. For both prostate and 
lung tumor motion, halved leaf width resulted in the largest 
tracking performance improvement.  
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Purpose/Objective: The clinical use of EBRT and BT dose 
accumulation for cervical cancer is hampered by the 
unknown dosimetric impact of unavoidable geometrical 
uncertainties originating from the non-rigid mapping of intra-
patient anatomies. In a recent study, these geometrical 
uncertainties were quantified for a novel non-rigid 
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registration method enabling mapping of greatly deformed 
and sliding tissues. In this study, we developed and report on 
the results of a straightforward method to translate this 
geometrical ground truth validation to uncertainties in the 
mapped dose and relevant dosimetric endpoints. 
Materials and Methods: For 9 cervical cancer patients, T2w-
MRIs acquired before EBRT and as part of the MRI-guided BT 
procedure (BT applicator inserted) were used. A recently 
developed and anatomically validated structure-wise 
registration with vector field integration (SW+VF) was used to 
map non-rigidly the EBRT and the BT scans. From the results 
of the anatomical validation, i.e. the residual distances after 
the transformation for structures and landmarks, the 
standard deviation of the residual vectors for each 
component were calculated: σx, σy, and σz. These standard 
deviations were applied in the construction of an ellipsoid 
with radius (2σx, 2σy, 2σz), which represents the volume in 
which 95% of the observations occur. Next, as we mapped the 
dose for a given position p, we collected the doses within the 
ellipsoid centered at p's mapped position. From these 
collected values, we calculated the 5 and 95 percentiles as 
measure of the uncertainty in the mapped dose per voxel. 
The uncertainty was calculated for mapping EBRT to BT and 
vice versa. To illustrate the uncertainties for clinically 
relevant scenarios, we summarized them using root mean 
squares for D2cc and D50% for the bladder, rectum and sigmoid. 
Results: The standard deviations of the residual vectors were 
σx=2.3, σy=2.7, and σz=2.9 mm. The uncertainties for 
mapping the EBRT and BT dose distribution are summarized 
in table 1. The mapped BT dose represents the dose of a 
single BT application. In general, the uncertainties in D2cc for 
mapping BT to EBRT dose distributions are higher than for 
mapping EBRT to BT dose. This can be explained by the high 
dose gradients in the BT dose distribution and the location of 
D2cc in the EBRT dose distribution. For EBRT dose mapping the 
uncertainties in D50% are larger compared with D2cc. 
 
 
 
Conclusions: The magnitudes of the dose mapping 
uncertainties caused by the registration uncertainty 
emphasize the need of estimating these values prior to any 
clinical application of dose mapping. The proposed procedure 
gives a conservative estimate of the uncertainty by assuming 
the same registration uncertainty for all voxels, and by 
collecting all doses within the uncertainty volume. Extending 
this procedure to include voxel-wise registration uncertainty 
and its shape is part of future research. 
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Purpose/Objective: The use of high dose modulated arc 
techniques for stereotactic ablative radiation therapy (SABR) 
with flattened or unflattened beams is now common 
practice. With these approaches there is an increase in 
monitor units (MU) and in irradiation time. Consequently it is 
important to ensure that patient breathing, and motion, 
remains within acceptable limits during treatment. Here a 
new method, PUMA, was developed to predict the effect of 
motion on modulated SABR lung cancer plans (interplay 
effect). 
Materials and Methods: On four-dimensional computerised 
tomographic (4DCT) images of 12 previously treated lung 
cancer patients 23 volumetric arc therapy (VMAT) plans were 
created using the Eclipse V.10 treatment planning system 
(TPS) (Varian Medical Systems, Palo Alto, USA). On six patient 
data sets, two plans with different level of modulation were 
created. Each plan was made up of four 6MV arcs of 
approximately 200o. Five additional plans of two 10MV FFF 
(flattening filter free) arcs of approximately 200º were also 
created. The plans were verified by irradiating radiochromic 
films (EBT 3, ISP Corp USA) placed within a Quasar 
Respiratory Motion Phantom (Quasar, Modus Medical Devices) 
on a Varian Silhouette and plans with FFF beams on a 
TrueBeam (Varian). Film Analysis was performed using the 
RIT 113 software (Radiological Imaging Technology, USA). 
Each plan was delivered twice on the Quasar phantom, the 
first without movement and the second with motion of 1 cm 
peak to peak at 12 breaths per minute (BPM). A relative 
comparison between the dose distributions measured and 
those calculated on the TPS was performed and the PUMA 
method used to analyse the effect of motion on the plans. 
The results were also compared to those obtained on the 
Quasar phantom. The criteria for evaluation was set to be < 
5% of points with gamma 3%,3 mm > 1% on the comparison 
between static and dynamic dose distributions recorded on 
radiochromic films and < 5% of points with > 3% difference 
dose between PUMA and the TPS. These were compared to 
the results obtained on the Quasar phantom.  
Results: Figure 1 shows the comparison between both 
methods where, except for plan 7, they agree on the pass 
criteria. In this case PUMA, which analyses all target 
volumes, fails while the radiochromic film passes. This 
suggests that PUMA, which analyses the volumetric dose 
distribution, is more sensitive to interplay effect analysis 
than the analysis performed on one plane by using Quasar. 
 
 
